Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis

Objective: Contezolid is an oxazolidinone antimicrobial agent newly approved for treatment of Gram-positive bacterial infections. It is primarily metabolized by the liver. This study aimed to assess whether it is required to adjust the dose of contezolid in patients with moderate hepatic impairment...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Junzhen, Yang, Xinyi, Wu, Jufang, Wang, Jingjing, Wu, Hailan, Wang, Yu, Yuan, Hong, Yang, Huahui, Wang, Hailin, Zhang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040594/
https://www.ncbi.nlm.nih.gov/pubmed/36992830
http://dx.doi.org/10.3389/fphar.2023.1135007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040594/
https://www.ncbi.nlm.nih.gov/pubmed/36992830
http://dx.doi.org/10.3389/fphar.2023.1135007

Ejemplares similares